Nuvation Bio stock rallied after Cantor initiated coverage with an 'Overweight' rating, while MongoDB stock gained following Evercore ISI's initiation with an 'Outperform' rating.

RBC Capital has reduced its price target for Nuvation Bio (NUVB) in its Q2 preview, indicating a revised outlook for the biotechnology company.

Nuvation Bio's stock has seen a significant 190% increase, but the article questions the implications of a recent $753,000 insider sale amidst this growth.

A veteran pharmaceutical venture capitalist insider has purchased 25,000 shares of Nuvation Bio, indicating confidence in the company as a new drug gains momentum.

Nuvation Bio Inc. provided a summary of its Q1 2026 earnings call, detailing its financial results and business updates for the period.

An analysis explores the potential revenue Nuvation Bio (NUVB) could generate from the sales of its drug, Ibtrozi.

Nuvation Bio Inc. is experiencing a bullish trend following positive developments in its regulatory pathway in Europe.

Nuvation Bio reported annual revenue of $62.9 million, following the successful launch of its product, Erozi.

Nuvation Bio Inc. has made amendments to the protocol for its Safusidenib trials, which are focused on treating astrocytoma.

DA Davidson has initiated coverage on Everus stock with a 'buy' rating, citing M&A growth potential, while Cantor Fitzgerald has started coverage on Nuvation Bio stock with an 'overweight' rating. These initiations reflect analyst confidence in the future performance of these companies.

Analysts are questioning if Nuvation Bio Inc (NUVB) stock has the potential to soar 150% from its current trading level.

XCharge has priced a $4.38 million registered direct offering, while Nuvation Bio has priced a $250 million convertible notes offering. These announcements detail recent financial activities by the respective companies.

Nuvation Bio (NUVB) stock has seen a significant increase, more than doubling its value year-on-year.

Nuvation Bio Inc. (NUVB) and Taysha Gene Therapies, Inc. (TSHA) have been highlighted as leading prospects within the healthcare penny stock market. These companies are asserted to be among the best investment opportunities in the sector.

Nuvation Bio has secured global rights from Daiichi Sankyo for a new brain cancer therapy, expanding its portfolio in oncology.

The European Medicines Agency (EMA) has accepted the application from Nuvation Bio and Eisai for taletrectinib, a drug intended for the treatment of non-small cell lung cancer (NSCLC).

Nuvation Bio's stock has seen a significant increase of 130% over the past year, attributed in part to a $3 million investment disclosed by a specific fund.

Wall Street analysts are offering their insights and predictions regarding the future trajectory of Nuvation Bio Inc. (NUVB).

Several companies, including Oscar Health, Optimum Communications, and Ormat Technologies, have released highlights from their second-quarter earnings calls. These reports provide updates on their financial performance and business operations for the recent quarter.

Nuvation Bio has increased its convertible notes offering to $287.5 million following the exercise of a greenshoe option.

Nuvation Bio announced its plan to offer $200 million in convertible senior notes, a financial move for the company.

Nuvation Bio anticipates its gross-to-net ratio to stabilize at approximately 30% as its drug IBTROZI shifts to over 50% TKI-naive starts. This outlook provides insight into the company's financial projections.

An analysis from Yahoo Finance focuses on Nuvation Bio Inc. and its potential for revenue generation from glioma treatments.

Wedbush analysts are bullish on Nuvation Bio after the company expanded its rights for the drug Safusidenib, signaling positive developments for the biotech firm.

Nuvation Bio Inc. (NUVB) and Eisai have received EMA (European Medicines Agency) validation for their drug Taletrectinib, moving it forward in the regulatory process.

RBC Capital has increased its price target for Nuvation Bio (NUVB) from $12 to $13, citing reasons for the upward adjustment.

Nuvation Bio has detailed its first-line IBTROZI growth strategy, highlighting a 50-month median duration of response and expanding global partnerships.